Results 11 to 20 of about 43,668 (144)

γ-Aminobutyric acid promotes vesicular stomatitis virus infection in mouse macrophages [PDF]

open access: yesJichu yixue yu linchuang, 2023
Objective To investigate the effect and mechanism of metabolite γ-aminobutyric acid (GABA) on viral infection to RAW264.7 cell lines and mouse primary peritoneal macrophages. Methods RAW264.7 cell lines were treated with 0,10,30,50 and 70 mmol/L GABA for
ZHAO Lu, LIU Yang
doaj   +1 more source

Vesicular Stomatitis Virus Elicits Early Transcriptome Response in Culicoides sonorensis Cells

open access: yesViruses, 2023
Viruses that are transmitted by arthropods, or arboviruses, have evolved to successfully navigate both the invertebrate and vertebrate hosts, including their immune systems. Biting midges transmit several arboviruses including vesicular stomatitis virus (
Stacey L. P. Scroggs   +3 more
doaj   +1 more source

Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner

open access: yesFrontiers in Immunology, 2021
Replication competent vesicular stomatitis virus (VSV) is the basis of a vaccine against Ebola and VSV strains are developed as oncolytic viruses. Both functions depend on the ability of VSV to induce adequate amounts of interferon-α/β.
Andreas Linder   +24 more
doaj   +1 more source

Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats

open access: yesBMC Veterinary Research, 2021
Background Vesicular stomatitis (VS) is an acute, highly contagious and economically important zoonotic disease caused by the vesicular stomatitis virus (VSV).
Xiaojuan Xue   +8 more
doaj   +1 more source

Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells

open access: yesMolecular Therapy: Oncolytics, 2021
The difficulty of glioblastoma treatment makes it a good candidate for novel therapies, such as oncolytic viruses. Vesicular stomatitis virus expressing Lassa virus glycoprotein (Lassa-VSV) showed significant promise in animal models using established ...
Teddy E. Kim   +8 more
doaj   +1 more source

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers

open access: yesMolecular Therapy: Oncolytics, 2020
Recombinant vesicular stomatitis virus (VSV)-fusion and hemagglutinin (FH) was developed by substituting the promiscuous VSV-G glycoprotein (G) gene in the backbone of VSV with genes encoding for the measles virus envelope proteins F and H. Hybrid VSV-FH
Bolni Marius Nagalo   +13 more
doaj   +1 more source

Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate modelResearch in context

open access: yesEBioMedicine, 2023
Summary: Background: Nipah virus (NiV) causes recurrent outbreaks of lethal respiratory and neurological disease in Southeast Asia. The World Health Organization considers the development of an effective vaccine against NiV a priority.
Emmie de Wit   +15 more
doaj   +1 more source

The Methyltransferase Region of Vesicular Stomatitis Virus L Polymerase Is a Target Site for Functional Intramolecular Insertion

open access: yesViruses, 2019
The L-protein of vesicular stomatitis virus (VSV) is a single-chain multi-domain RNA-dependent RNA polymerase. Previously reported attempts of intramolecular insertions of fluorescent proteins into the L-protein resulted in temperature-sensitive and ...
Emmanuel Heilmann   +7 more
doaj   +1 more source

Transmission and pathogenesis of vesicular stomatitis viruses

open access: yesBrazilian Journal of Veterinary Pathology, 2009
Vesicular Stomatitis (VS) is caused by Vesicular stomatitis viruses (VSV), negative single stranded RNA arthropod-borne members of the Family Rhabdoviridae.
Janildo L. Reis Jr   +3 more
doaj   +1 more source

Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia

open access: yesHuman Vaccines & Immunotherapeutics, 2017
Ebola hemorrhagic fever, also known as Ebola virus disease or EVD, is one of the most dangerous viral diseases in humans and animals. In this open-label, dose-escalation clinical trial, we assessed the safety, side effects, and immunogenicity of a novel,
I. V. Dolzhikova   +35 more
doaj   +1 more source

Home - About - Disclaimer - Privacy